Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
RhoA pathway
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "RhoA pathway" in MCE Product Catalog:
24
Category:
Alkaloids Plant Narcissus tazetta Linn. var. chinensis M.Roemer Extract Amaryllidaceae Extract Disease Research Fields Isoquinoline Alkaloids Cancer Agricultural Research
Target:
6
3
3 Cited Publications
Target:
Research Areas:
JMS-053 is an efficient and reversible PTP4A3 inhibitor, with an IC50 value of 18 nM.
JMS-053 demonstrates broad PTP4A inhibitory activity with IC50s of 50 nM and 53 nM for PTP4A1 and PTP4A2, respectively. JMS-053 exhibits IC50 values of 92.6 nM and 207.6 nM for CDC25B and DUSP3, respectively. JMS-053 can effectively inhibit the activity of PTP4A3, inhibit tumor cell proliferation and migration through multiple mechanisms such as interfering with RhoA and STAT3/p38 signaling pathway. JMS-053 can be used for the study of cancers such as ovarian cancer, breast cancer and colon cancer .
3
3 Cited Publications
Cat. No.: HY-N2322
CAS No.: 32449-98-2
Category:
Alkaloids Piperidine Alkaloids Plant Disease Research Fields Cancer Solanaceae Extract Solanum nigrum Linn. Extract
Target:
2
2 Cited Publications
Target:
Research Areas:
CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
2
2 Cited Publications
Research Areas:
UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis .
Cat. No.: HY-N0168A
CAS No.: 69097-99-0
Target:
Cat. No.: HY-168596
CAS No.: 3062142-82-6
RhoA-ROCK-IN-1 (Compound b19) is an inhibitor of RhoA/ROCK. RhoA-ROCK-IN-1 can significantly inhibit cell proliferation, migration, and invasion, while promoting cell apoptosis. RhoA-ROCK-IN-1 demonstrates remarkable anticancer activity by inhibiting the RhoA/ROCK pathway .
Cat. No.: HY-150187
CAS No.: 1246430-04-5
Target:
Research Areas:
20:4 Lyso PI acts as an activator of GPR55 and RhoA. 20:4 Lyso PI activates the GPR55-RhoA-ROCK pathway, thereby inducing morphological changes, cytoskeleton assembly, cell rounding and stress fiber formation. 20:4 Lyso PI can be used in research related to diseases such as those of the nervous system .
Cat. No.: HY-16563R
CAS No.: 29477-83-6
Synonyms: Lycoricidinol (Standard)
Category:
Alkaloids Plant Narcissus tazetta Linn. var. chinensis M.Roemer Extract Amaryllidaceae Extract Isoquinoline Alkaloids
Target:
Synonyms: 10-Ethenyl-19-norprogesterone
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Org OD 02-0 (10-Ethenyl-19-norprogesterone) is a selective mPRα/PAQR7 agonist that can cross the blood-brain barrier. Org OD 02-0 targets mPRα with an IC50 of 33.9 nM and activates the PI3K-AKT, MAPK/ERK, and Src signaling pathways. Org OD 02-0 upregulates SERCA2, phosphorylates phospholamban, increases sarcoplasmic reticulum calcium uptake, decreases RhoA/ROCK activity, and induces vascular smooth muscle relaxation and nitric oxide production. Org OD 02-0 can be used for research on Parkinson's disease, glioblastoma, apnea, and hypertension .
Cat. No.: HY-N0168AS1
CAS No.: 2750534-85-9
Cat. No.: HY-N2322R
CAS No.: 32449-98-2
Target:
Cat. No.: HY-N0168AR
CAS No.: 69097-99-0
Target:
Cat. No.: HY-N0168AS
CAS No.: 1346605-26-2
Cat. No.: HY-108361R
CAS No.: 1443437-74-8
Target:
Research Areas:
CCG-203971 (Standard) is the analytical standard of CCG-203971 (HY-108361). This product is intended for research and analytical applications. CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
Cat. No.: HY-123958
CAS No.: 785774-34-7
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
